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In patients with diabetes mellitus, foot infections pose a significant risk. These are complex
infections commonly caused by Staphylococcus aureus, Pseudomonas aeruginosa and
Acinetobacter baumannii, all of which are potentially susceptible to bacteriophages. Here, we
characterized five bacteriophages that we had determined previously to have antimicrobial and
wound-healing potential in chronic S. aureus, P. aeruginosa and A. baumannii infections.
Morphological and genetic features indicated that the bacteriophages were lytic members of the
family Myoviridae or Podoviridae and did not harbour any known bacterial virulence genes.
Combinations of the bacteriophages had broad host ranges for the different target bacterial
species. The activity of the bacteriophages against planktonic cells revealed effective, early killing
at 4 h, followed by bacterial regrowth to pre-treatment levels by 24 h. Using metabolic activity as
a measure of cell viability within established biofilms, we found significant cell impairment
following bacteriophage exposure. Repeated treatment every 4 h caused a further decrease in cell
activity. The greatest effects on both planktonic and biofilm cells occurred at a
bacteriophage : bacterium input multiplicity of 10. These studies on both planktonic cells and
established biofilms allowed us to better evaluate the effects of a high input multiplicity and a
multiple-dose treatment protocol, and the findings support further clinical development of
bacteriophage therapy.
INTRODUCTION
Diabetes mellitus affects an estimated 171 million patients
worldwide (Wild et al., 2004) and has become a major
world epidemic. Even with the best preventative care, 9%
of patients will develop a diabetic foot infection (DFI),
which brings the consequent risk of amputation (Lavery et al.,
2006). Qualitative and quantitative aspects of wound micro-
biology are critical determinants of the wound outcome.
Gram-positive micro-organisms are the first to colonize and
acutely infect breaks in the skin, whereas chronic wounds
develop a more complex polymicrobial microbiology,
including aerobic Gram-negative rods (Lipsky et al., 2004).
Abbreviations: AB, alamarBlue; BT, bacteriophage therapy; DFI, diabetic
foot infection; IM, input multiplicity; NCBI, National Center for
Biotechnology Information; p.i. post-infection.
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These micro-organisms aggregate in communities encased
within extracellular polymeric substances on the wound
surface. Such an entity is defined as a biofilm, and shows
increased resistance to immunological and antimicrobial
attack (Percival et al., 2012). In current clinical practice, DFI
treatment includes debridement and systemic antibiotics
(Lipsky et al., 2004). The increased incidence of antibiotic-
resistant bacterial strains, such as meticillin-resistant Sta-
phylococcus aureus and pan-drug-resistant, non-fermenting,
Gram-negative bacilli, threatens the efficacy of antimicrobial
therapy (Mendes et al., 2012). Thus, it is necessary to identify
new therapeutic strategies for DFIs.
Bacteriophages are viruses that consist of a genome con-
tained within a protein coat and that specifically infect
bacteria. In contrast to filamentous bacteriophages, the
multiplication of tailed bacteriophages and release of
the newly formed virus particles always involves lysis of
the host bacterial cell. However, among tailed bacterio-
phages, some may not immediately follow this lytic pathway.
The genome of these so-called temperate bacteriophages
may instead reside in the host cell (integrated in the bacterial
chromosome or in a plasmid-like form in the cytoplasm)
and be propagated for several bacterial generations without
lysis. In contrast, strictly lytic phages do not have this option
and usually undergo the lytic pathway once inside the
bacterial host (Ansaldi, 2012). Bacteriophage therapy (BT)
is the use of lytic bacteriophages to reduce or elimi-
nate pathogenic bacteria. BT has become a broadly relevant
technology for veterinary, agricultural and food microbio-
logical applications; however, the treatment of human
infections with BT attracts the greatest interest (Kutter
et al., 2010).
The use of bacteriophages as antibacterial agents for
suppurative infections began shortly after the discovery of
bacteriophages. Bruynoghe and Maisin first demonstrated
BT, using bacteriophages to treat S. aureus skin infections
(Bruynoghe & Maisin, 1921). However, following the
discovery and general application of antibiotics, interest in
the therapeutic uses of bacteriophages waned. Recently, the
increase in antibiotic-resistant bacterial strains has reinvi-
gorated enthusiasm about these bacteria-specific viruses
(Chopra et al., 1997). This interest is particularly true in
cases in which bacteriophages can be applied externally
(topical application), as is the case for DFIs.
The development of an effective BT is a multistep process
consisting of: (i) bacteriophage isolation and assessment
for antibacterial activity against specific bacterial strains;
(ii) bacteriophage characterization and screening for un-
desirable traits; (iii) in vitro posology and dosage regimen
design; (iv) pre-clinical animal efficacy and toxicology
studies; and (v) regulated human clinical trials. Although
the use of bacteriophages to treat DFIs is promising,
difficulties in any of these steps can hinder widespread
clinical application (Abedon, 2010).
Recently, we demonstrated the antimicrobial activity and
wound-healing capability of a topically delivered bacteriophage
suspension against wounds chronically infected with chronic
S. aureus, Pseudomonas aeruginosa and Acinetobacter bau-
mannii in two animal models of diabetes mellitus (Mendes
et al., 2013). In the current study, we present a character-
ization of the bacteriophages used in this previous study. We
examined their spectrum of activity, genetic and morpho-
logical structures, and activity against planktonic cells and
established biofilms. Collectively, the findings justify the
posology and dosage regimen used in the animal studies.
METHODS
Bacterial strains. The S. aureus 743/06, P. aeruginosa 433/07 and A.
baumannii 1305/05 host strains were isolated from human clinical
samples that were collected and identified in hospitals in the Lisbon
area. The three strains were characterized previously as biofilm
producers (Mottola et al., 2013). Bacterial clinical isolates used for
bacteriophage host-range investigation included S. aureus (n5132), P.
aeruginosa (n593) and A. baumannii (n5103) from wound speci-
mens. Of these isolates, 44 were from DFIs. The epidemiology, clinical
details and specific microbiology of our collection of DFI isolates have
been described previously (Mendes et al., 2012). All isolates were
stored in tryptone soy broth (TSB; Biokar Diagnostics) with 15%
glycerol (w/v) at 270 uC until needed. For the experiments, single
bacterial colonies were grown in TSB at 37 uC. After a 24 h incu-
bation, the bacterial cells were suspended in saline and adjusted to
McFarland’s scale 0.5 (bioMe´rieux), producing a final working
suspension of approximately 5.06108 c.f.u. ml21.
Bacteriophage isolation, amplification and purification. S.
aureus F44/10 and F125/10, P. aeruginosa F770/05 and F510/08, and
A. baumannii F1245/05 bacteriophages were isolated from envir-
onmental water samples from the Lisbon area. Standard methods for
bacteriophage isolation (Adams, 1959) were employed for all five
bacteriophages using the host strains described above. The obtained
bacteriophage plaques were purified by repeated single plaque isolation
to ensure that each contained only one type of bacteriophage.
To produce bacteriophage stocks in sufficient quantities for the
experiments, a previously described protocol of amplification,
concentration by high-speed centrifugation and purification on a
CsCl gradient (Miller, 1987) was used for all five bacteriophages.
Briefly, a final lysate of each bacteriophage was centrifuged at 10 000 g
for 20 min at 4 uC. The pellet was discarded, and the supernatant
fraction was concentrated overnight at 8000 r.p.m. (JA-14 rotor;
Beckman Coulter). The bacteriophage pellet was resuspended in SM
buffer (5.8 g NaCl l21, 2 g MgSO4.7 H2O l
21, 50 ml 1 M Tris/HCl,
pH 7.5). This concentrated bacteriophage suspension was loaded
onto a discontinuous CsCl gradient and centrifuged at 30 000 r.p.m.
for 5 h at 4 uC in a Beckman L-90 ultracentrifuge with an SW41Ti
rotor (Beckman Coulter). The banded bacteriophage particles were
collected and thoroughly dialysed against SM buffer. Final bacterio-
phage titres were determined using double agar overlay plaque assays
(Kropinski et al., 2009). Purified bacteriophages were stored at 4 uC
and further diluted in SM buffer to achieve a working suspension of
approximately 261010 p.f.u. ml21 prior to the assays.
Morphology of bacteriophages. The morphology of each of the
five bacteriophages was analysed by transmission electron microscopy
at the Fe´lix d’He´relle Reference Center for Bacterial Viruses, Laval
University, Que´bec, Canada. Briefly, a 200-mesh Formvar carbon-
coated copper grid (Pelco International) was deposited face down on
10 ml staining suspension (2% uranyl acetate, pH 7.0, for all bac-
teriophages except for F770/05, which was stained with 2% phos-
photungstic acid, pH 7.0). After 30 s, 10 ml bacteriophage suspension
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was mixed with the stain. After 2–3 min, the grid was deposited face up
on blotting paper. The grid was dried for 5 min and then observed at
80 kV using a JEOL 1230 transmission electron microscope. These data
were integrated with the genomic analysis, and the bacteriophages were
classified according to the Ackermann (2009) classification.
Genomic analysis of bacteriophages. The DNA of all five
bacteriophages was isolated using a standard phenol/chloroform
extraction and DNA precipitation protocol (Sambrook et al., 1989).
The purified nucleic acid was sent to Macrogen for commercial
sequencing. In brief, pyrosequencing of the sample DNA was
performed using a GS FLX Titanium General Library Preparation
kit (Roche 454 Company) according to the manufacturer’s instruc-
tions. The assembly of quality-filtered reads was performed using
Genome Sequencer De novo Assembler software (Newbler) version
2.5.3. An extensive bioinformatics evaluation was conducted to
analyse the sequences and identify regions of similarity with entries in
databases, which yield clues about structure and function. Each
genome sequence was scanned using the National Center for
Biotechnology Information (NCBI) BLASTN and BLASTX bioinformatics
tools (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Prediction of ORFs was
performed by integrating the results obtained by the programs
GeneMark.hmm (http://exon.gatech.edu/genemark/eukhmm.cgi) and
MetaGeneAnnotator (http://metagene.cb.k.u-tokyo.ac.jp). Protein homo-
logy searches were performed with the BLASTP program (http://blast.
ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) using the NCBI non-
redundant protein sequence database. The genome sequences were
deposited in the patent division of GenBank (specific patent nos:
WO2010090542 and WO2012036580).
Bacteriophage host range. The five bacteriophages were tested
against a panel of clinical isolates using the bacteriophage spot-test
procedure (Armon & Kott, 1993). Briefly, 3 ml top-0.7% tryptone
soy agar (TSA; Biokar Diagnostics) was added to 200 ml overnight
culture of each clinical isolate and poured over TSA. The agar was
allowed to solidify, after which 5 ml each bacteriophage suspension
(approx. 108 p.f.u.) was spotted on the bacterial lawn of each different
isolate. The drop was allowed to dry, and the plates were incubated
overnight at 37 uC. Specific bacteriophage-sensitive isolates showed
clear areas where the bacteriophage suspensions had been spotted.
Bacteriophage activity against planktonic cells. To determine
the activity of the bacteriophages against planktonic cells in vitro, a
kinetic time–kill assay (NCCLS, 1999) was performed using a modified
protocol. Briefly, 1 ml host bacterial suspension (56108 c.f.u.) was
diluted in 9 ml TSB, yielding a final concentration of 56107 c.f.u.
ml21. For single-bacteriophage studies, 100 ml (56109 p.f.u.) specific
bacteriophage was added, yielding a final concentration of 56108 p.f.u.
ml21 [input multiplicity (IM) of bacteriophage : bacterium of 10]. For
combination studies, 100 ml (56109 p.f.u.) each bacteriophage
suspension was added, resulting in a final concentration of 56108
p.f.u. ml21 (IM of 10) for each of the bacteriophages. An additional
kinetics assay was performed for P. aeruginosa 433/07, in which 10 ml
(56108 p.f.u.) bacteriophage F770/05 suspension was added (yielding
an IM of 1), alone or in combination with the bacteriophage F510/08 at
an IM of 10. Control experiments were performed in parallel using
bacteriophage buffer instead of a bacteriophage suspension. All
mixtures were incubated at 37 uC with agitation, and 100 ml aliquots
were collected at 0, 1, 3, 5 and 24 h post-infection (p.i.). Bacterial
quantification was performed using a 10-fold serial dilution method
(Murray et al., 2003). All experiments were conducted in triplicate. The
results are presented as the mean±SD and are expressed as log-
transformed values [log (c.f.u. ml21)] over time.
Combined bacteriophage activity against established biofilms.
The activity of the bacteriophages against established biofilms was
examined using a modification of previously described protocols
(Cerca et al., 2005; Pettit et al., 2005). Briefly, 1 ml of each of the host
bacterial suspensions (56108 c.f.u.) was diluted in 9 ml TSB, and
100 ml of this dilution (56106 c.f.u.) was added to a 96-well flat-
bottomed polystyrene microtitre plate (Orange Scientific) and
incubated at 37 uC for 24 h to allow biofilm formation. After
incubation, the planktonic bacteria were removed carefully with a
sterile pipette. The number of biofilm cells at 24 h has been
demonstrated previously to be approximately 107 c.f.u. per well for
all bacterial species (Mottola et al., 2013). Next, 150 ml bacteriophage
suspension (IMs of 10 and 100) diluted in TSB was added to the wells.
The following bacteriophage suspensions were used for each
bacterium: for S. aureus, a 1 : 1 combination of F44/10 and F125/10;
for P. aeruginosa, a combination of F770/05 and F510/08 at a 1 : 10
ratio; and for A. baumannii, F1245/05 alone. Biofilms treated with
TSB alone served as positive controls in measurements of cell
metabolic activity (see below).
The microplates were incubated at 37 uC for 4 or 24 h. At each time
point, the wells were processed according to a previously described
protocol (Pettit et al., 2005) using alamarBlue (AB; Thermo
Scientific), and their absorbance at 570 and 600 nm was measured
using a SpectraMax 340PC microplate reader (Molecular Devices). A
second assay was performed in which, after biofilm formation,
planktonic bacteria were removed from the wells and replaced with a
bacteriophage suspension every 4 h over a 24 h incubation period. In
the positive-control group, planktonic bacteria were removed from
the wells and replaced with TSB every 4 h. These plates were then
processed as described previously (Pettit et al., 2005).
Biofilm susceptibility experiments were performed a minimum of
three times. All results are presented as the percentage variation of
AB±SD. This value was calculated using the manufacturer’s formula,
with one exception: the medium-only negative control in the formula
was replaced by a more robust negative control that consisted of
medium plus bacteriophage at each IM (i.e. IMs of 10 and 100).
Strong antimicrobial suppression was defined as a ¢50% reduction
in AB compared with the positive control.
Statistical analysis. For all datasets, comparisons between groups
were performed using two-tailed Student’s t-tests, and values of
P,0.05 were considered significant. All data were entered into a
spreadsheet program (Excel; Microsoft) for statistical analysis.
Analytical statistics were performed using Analyse-it, version 2.21
Excel 12+ (Analyse-it Software), a statistical add-in program for Excel.
RESULTS
Bacteriophage features
After purification, the selected bacteriophages were initially
characterized according to plaque morphology. The S.
aureus F44/10 and F125/10, P. aeruginosa F770/05 and
F510/08, and A. baumannii F1245/05 bacteriophages pro-
duced clear lytic plaques ranging from 1.5 to 5 mm in
diameter. Plaques produced by the bacteriophages F770/05,
F510/08 and F1245/05 were surrounded by growing opaque
halo zones. The morphological and genomic characteristics
of the five bacteriophages are presented in Fig. 1.
Morphology
To classify the purified bacteriophages based on their
virion morphology, we used transmission electron micro-
scopy. The staphylococcal bacteriophages F44/10 and F125/
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10 appeared to be composed of a contractile tail and an
isometric head, with a baseplate structure also discernible
at the tip of the F44/10 tail. These features, along with their
genomic properties (see below), allowed us to classify F44/
10 and F125/10 as members of the family Myoviridae. The
Pseudomonas bacteriophages F770/05 and F510/08 and the
Acinetobacter bacteriophage F1245/05 had short tails and
were classified as members of the family Podoviridae. The
family Podoviridae consists of different subgroups. Although
there are certain morphological similarities between the
bacteriophages F510/08 and F1245/05 and the wKMV-like
group (Chang et al., 2011; Lammens et al., 2009), definite
morphological assignment of F1245/05 could not be
performed due to the uncharacteristic morphology of these
virion particles.
Genomic analysis
The bacteriophages were characterized at the genomic level
by determining and analysing their genome sequences. The
bacteriophages F44/10 and F125/10 had the largest
genomes and hence a greater number of putative genes
and ORFs, which is in agreement with the characteristic
features of viruses belonging to the family Myoviridae
(Lavigne et al., 2009). The genomes of the bacteriophages
F44/10 and F125/10 displayed high similarity (up to 98%
nucleotide sequence identity, 80–90% genome coverage)
to those of a group of highly related staphylococcal
myoviruses, which includes bacteriophages K (O’Flaherty
et al., 2004), A5W (GenBank accession no. EU418428) and
GH15 (Gu et al., 2012). The bacteriophages F510/08 and
F770/05 shared high sequence identity (up to 98% nucleo-
tide sequence identity, 83–98% genome coverage) with
Pseudomonas wKMV-like and N4-like viruses, respectively
(Ceyssens et al., 2010). Examples of wKMV-like viruses are
the bacteriophages wKMV and LUZ19 (Ceyssens et al.,
2006; Lavigne et al., 2003) and of N4-like viruses are LIT1
and LUZ7 (Ceyssens et al., 2010). The bacteriophage
F1245/05 presented no significant similarity at the DNA
level with any known bacteriophage in the databases,
except for a few short segments with up to 4% nucleotide
sequence identity and 81% genome coverage.
The deduced products of the predicted genes of all
bacteriophages were compared with sequences in the
NCBI non-redundant protein sequence database using
BLASTP. No significant similarity with known virulence or
toxin proteins or with elements typically associated with
lysogeny (integrases, repressors and antirepressors) could
be found. Finally, the protein similarity searches did not
reveal potential exopolysaccharide depolymerase genes.
Bacteriophage host range
To gain insight into the host range of selected bacter-
iophages, the susceptibility of three panels of clinical
isolates of S. aureus (n5132), P. aeruginosa (n593) and A.
S. aureus P. aeruginosa
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Fig. 1. Morphological and genomic characteristics of the bacteriophages used for BT. Five bacteriophages previously shown to
successfully treat infections in vivo were characterized using transmission electron microscopy. Representative images are
shown. The genomes were sequenced by pyrosequencing and analysed extensively using BLASTN, BLASTX, GeneMark.hmm,
MetaGeneAnnotator and BLASTP. ICTV, International Committee on the Taxonomy of Viruses.
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baumannii (n5103) was tested for each species-specific
bacteriophage. There was a degree of variability in the host
range of each bacteriophage (Table 1). All tested staphylo-
coccal strains were susceptible to both S. aureus bacter-
iophages (F44/10 and F125/10). In contrast, when examined
individually, the P. aeruginosa bacteriophages F770/05 and
F510/08 lysed only 63.4 and 68.8% of the tested isolates,
respectively. However, when these results were considered
together, we observed that 80.6% of the P. aeruginosa
isolates were infected by at least one of the bacteriophages,
whereas 51.6% were susceptible to both bacteriophages.
Finally, of the tested A. baumannii strains, 74.8% were
susceptible to the bacteriophage F1245/05.
Bacteriophage activity against planktonic cells
To evaluate the activity of the selected bacteriophages
against planktonic cells, liquid cultures of the different
bacterial hosts were exposed to the corresponding bacter-
iophages, both individually and in combination, and cell
growth/viability was monitored over time with constant
agitation. The time–kill curves are presented in Fig. 2. S.
aureus 743/06, when challenged with either F44/10 or F125/
10 at an IM of 10, showed impaired growth, with
reductions in cell counts of 2.3±0.3 and 2.2±0.2 log
(c.f.u. ml21), respectively, at 3 h p.i. However, after 24 h,
the cultures recovered to near-control levels. The reduction
in the number of viable cells observed at 3 h was
significantly enhanced when the two bacteriophages were
used in combination [3.4±0.2 log (c.f.u. ml21); P,0.01].
Nevertheless, there was no difference in the recovery of
growth at 24 h.
At an IM of 10, the P. aeruginosa bacteriophage F510/08
caused a 3.9±0.4 log (c.f.u. ml21) reduction in the viability
of P. aeruginosa 433/07 at 3 h p.i. This reduction was more
modest [0.7±0.4 log (c.f.u. ml21)] for F770/05 at the same
IM and time point. When the two bacteriophages were
combined, the kill curve was not different from that of
F770/05 for the first 5 h; however, the combination
provided a statistically significant reduction relative to
the control at 24 h [1.3±0.3 log (c.f.u. ml21); P,0.01].
When the IM of F770/05 was reduced to 1, combined with
F510/08 at an IM of 10, the initial 3 h reduction was more
pronounced [2.5±0.4 log (c.f.u. ml21); P,0.01]. Similarly,
this combination caused a statistically significant reduction
[1.7±0.3 log (c.f.u. ml21); P,0.01] relative to the control
at 24 h. A. baumannii 1305/05 suffered an initial 2.7±0.2
log (c.f.u. ml21) reduction at 3 h after single-bacteriophage
(F1245/05) challenge. Although this bacterial strain recov-
ered by 24 h, it did not reach the control levels of viability.
Activity of bacteriophage combinations against
established biofilms
We also studied the ability of the bacteriophages to eliminate
cells in established biofilms by treating biofilms with species-
specific bacteriophage combinations. AB, which quantita-
tively measures cell metabolic activity using an oxidation–
reduction indicator that changes colour in the presence of
metabolically active cells, was used to measure cell viability
in biofilms with and without treatment. The viability of cells
within a biofilm is one of the most important aspects when
evaluating the effectiveness of antimicrobial agents; there-
fore, we used a quantification method based on metaboli-
cally active cells, as determined by AB. This assay is a reliable
and reproducible method for evaluating biofilm suscept-
ibility and is considered to be preferable over the viable
plate-count method, as it is very difficult to recover all
surviving adherent bacteria as single cells using the latter
method (Pettit et al., 2005). The AB-based assay has been
used to identify antimicrobials with enhanced efficacy
against certain clinically important bacterial biofilms
(Pettit et al., 2005, 2009).
Fig. 3 shows the percentage of AB reduction in control and
treated biofilms at 4 and 24 h using different IMs and
frequencies of application. At 4 h, the tested bacteriophage
preparations strongly reduced the cell viability of all
bacterial hosts, independently of the IM. There was only
a statistically significant difference between IMs for A.
baumannii; the higher IM resulted in a greater reduction in
metabolic activity (71.9±5.8 vs 88.7±3.1%; P,0.01).
At 24 h, after a one-time bacteriophage preparation
application, the cell viability of all bacterial strains was
less suppressed than at 4 h but still significantly different
from that of the control. At 24 h, there were no statistically
significant differences between IMs except for S. aureus, for
which the higher IM resulted in a greater reduction in cell
viability (34.8±8.5 vs 52.6±7.7%; P,0.01). In experi-
ments using multiple bacteriophage treatments, a greater
reduction in cell viability was observed compared with the
reduction following one-time bacteriophage treatment.
Table 1. Susceptibility of wound bacterial isolates to candidate bacteriophages for BT
S. aureus P. aeruginosa A. baumannii
F44/10 F125/10 F770/05 F510/08 F770/05+F510/08 F1245/05
No. bacterial strains tested 132 93 103
Bacterial strain susceptibility (%) 100 100 63.4 68.8 80.6* 74.8
*Percentage of P. aeruginosa isolates that were susceptible to at least one of the bacteriophages (only 51.6% of the isolates were susceptible to both).
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Fig. 2. Time-kill curves of the target bacteria during planktonic growth when challenged with their specific bacteriophages
(alone or in combination). Bacterial strains were grown in TSB with constant agitation and with or without bacteriophages.
Growth was monitored and quantified by calculating cfu/ml at 0, 1, 3, 5, and 24 hours. In the left panel (input multiplicity, IM 10/
10), assays were performed on S. aureus 743/06, P. aeruginosa 433/07, and A. baumannii 1305/05 in which the specific
bacteriophage suspensions were added to provide an IM of 10. In the right panel (IM 10/1), an additional assay was performed
on P. aeruginosa 433/07 in which the bacteriophage F770/05 suspension was added to provide an IM of 1, alone or in
combination with the bacteriophage F510/08 at an IM of 10.
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This trend was found for S. aureus and P. aeruginosa but
not for A. baumannii.
DISCUSSION
Effective bacteriophage preparations for therapeutic pur-
poses require careful design through a multistep research
process of bacteriophage characterization, cocktailing and
dosing. This process includes in vitro studies, such as those
presented here, and in vivo studies, which have been
published previously (Mendes et al., 2013). Ideally, the
characterization of bacteriophages for BT should be as
thorough and complete as possible. However, in certain
cases, it may be more practical to minimize this process
and to focus the characterization on particular traits that
are the most desirable for a specific application. Combining
different bacteriophages in the same preparation (mixtures
of two or more bacteriophages within a given formulation)
frequently results in a broader spectrum of antibacterial
activity and/or lytic efficacy and may allow targeting of
bacteria under different conditions or in different environ-
ments (Chan & Abedon, 2012). Finally, in vitro experi-
ments such as those described in this work are useful for
evaluating the direct interaction between a drug and bac-
teria, which enables the selection of candidate bacteriophages.
These studies also provide valuable information for the
determination of optimal posology (Abedon & Thomas-
Abedon, 2010).
Integration of the information emerging from the mor-
phological and genomic analyses revealed that the bacter-
iophages used here were all tailed bacteriophages (order
Caudovirales), with two belonging to the family Myoviridae
and three to the family Podoviridae. Genome sequence
analysis did not identify any known genes related to
lysogeny or traits that might enhance the virulence of
the target bacteria, which is an important observation
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Fig. 3. Analysis of the activity of the bacteriophages against bacterial biofilms. Bacteria were grown for 24 h to establish
biofilms and the bacteriophages were then added. The following bacteriophage suspensions were used for each bacterium: for
S. aureus, a 1 : 1 combination of F44/10 and F125/10; for P. aeruginosa, a combination of F770/05 and F510/08 at a 1 : 10
ratio; and for A. baumannii, F1245/05 alone. Cell metabolism was quantified with AB and is reported as the percentage
reduction relative to growth in untreated controls. C, negative control; T, treated with bacteriophage; 1!, one-time
bacteriophage suspension application, 6!, bacteriophage suspension application every 4 h for 24 h. *P,0.01 (square brackets
indicate the comparisons between different groups).
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regarding the safe use of bacteriophages. Another import-
ant selection criterion for bacteriophages for BT is their
host range, which should be as broad as possible, par-
ticularly including clinically prevalent bacterial species (Gill
& Hyman, 2010). In this study, members of family Myo-
viridae exhibited the broadest spectrum of lytic activity,
whereas viruses of the family Podoviridae exhibited a
narrower spectrum, particularly the pseudomonal bacter-
iophages. The spectrum of activity of the staphylococcal
bacteriophages was relatively broad as expected, given
their high relatedness to bacteriophages K and A5W, both
of which have been described previously as polyvalent
bacteriophages (O’Flaherty et al., 2005; GenBank accession
no. EU418428). Nevertheless, the host ranges of the Pseu-
domonas and Acinetobacter bacteriophages were remarkable
compared with those of other species-specific bacterio-
phages (Merabishvili et al., 2009; Popova et al., 2012). The
overall morphology, genomic characterization and host-
range results suggested that these bacteriophages are very
good candidates for BT. However, care must be taken when
generalizing these results, because the bacterial clinical
isolates used for the bacteriophage host-range investigation
reflect only the microbiological profile of diabetic foot
ulcers in a particular geographical area, and these vary
worldwide. Also the sensitivity of the spot test must be
taken into account. Whilst the use of high bacteriophage
titres (108 p.f.u. per spot) for host-range analysis is routine
when considering bacteriophages for BT (Kutter, 2009), it
should be noted that the use of lower titres may reduce
host-range. In our host-range investigation, the use of
bacteriophage stock dilutions up to 103 p.f.u. per spot
yielded differences from the presented results by up to 23%
(unpublished data).
Time–kill curves provide detailed information about
antimicrobial efficacy against planktonic bacteria as a
function of time. These curves are often used to study the
antibacterial effect of single and combination drug
compounds and dosing regimens before in vivo efficacy
studies (NCCLS, 1999). In the current study, following
bacteriophage exposure, all bacteria had an initial bacterial
reduction to a nadir between 1 and 3 h p.i., followed by
regrowth that was noticeable after 5 h and even more
pronounced after 24 h. The Pseudomonas bacteriophage
combination resulted in a significantly greater reduction
in bacteria compared with the reduction stimulated by
most active single bacteriophage 24 h after bacteriophage
exposure. However, the decrease was insufficient to be
considered as a synergistic effect, defined as a¢2 log (c.f.u.
ml21)-fold decrease by a combination compared with the
most active single agent (NCCLS, 1999). In the Pseu-
domonas combination study, when an IM of 1 was used for
the Pseudomonas F770/05 bacteriophage instead of an IM
of 10, we observed a greater initial bacterial reduction after
3 h, but similar results were obtained at 24 h. This
interaction was not specifically analysed in our study,
and there is no obvious explanation for this, but clearly
further studies would be of interest.
The study presented here has certain limitations. First, only
a single bacterial inoculum was used. This value was care-
fully selected based on several lines of evidence. A higher
inoculum (107 c.f.u. ml21) was used than the normal 105
c.f.u. ml21 inoculum used in previous time–kill studies
testing antibiotics (NCCLS, 1999) because we wanted to
mimic a worst-case scenario, similar to that found in
wounds (Loc-Carrillo et al., 2012). In a previous epide-
miological study (Mendes et al., 2012), microbiological
products (aspirates, biopsies and swabs collected using the
Levine method) of clinically infected foot ulcers in patients
with diabetes were found to have a maximum bioburden of
107 c.f.u. (g tissue)21 (or cm22 of ulcer area). Additionally,
the most recent study using a previously optimized rodent
model (Mendes et al., 2013) tested this bacteriophage
cocktail on infected wounds with a known mean wound
bioburden of 7.54±0.19 log (c.f.u.) per ulcer.
Secondly, the IM in nearly all experiments was 10 (fixed
IM). The final IM chosen was selected based on the
‘multiplicity of 10 rule’, which states that if the goal is a
significant reduction in bacterial density, then one should
strive for in the order of 10 bacteriophages adsorbed to the
average bacterium (Abedon, 2009; Kasman et al., 2002).
Previous studies on infected animal and human burn tissue
have concluded that low-titre bacteriophage administra-
tion (IMs lower than 10) is unlikely to be successful
(Goode et al., 2003; Kumari et al., 2010). Furthermore,
increasing the IM increases the success of BT by reducing
bacterial numbers.
Thirdly, we observed regrowth in planktonic cells exposed
to bacteriophages within 24 h. This observation may be
indicative of the development of resistance, as in vitro
resistance is frequent in both BT and antibiotic therapy.
For example, a study (O’Flynn et al., 2004) previously
found in vitro resistance frequencies of 1026–1024 for
single-phage treatments and 1026 for double-phage or
triple-phage cocktails against Escherichia coli O157 :H7.
Similarly, resistance to fusidic acid can readily be selected
from an initial high inoculum, with a mean frequency of
1026–1028. This resistance has not limited the antibiotic’s
topical use and does not appear to be a clinical problem
(Sahm et al., 2013; Turnidge & Collignon, 1999). However,
these observations do not imply in vivo resistance.
According to certain studies, the rate of development of
resistance to bacteriophages is approximately 10-fold lower
than the rate of the development of antibiotic resistance
(Carlton, 1999). Nonetheless, as observed here, in vitro
studies show that bacteriophage resistance can evolve
within hours, independently of the use of bacteriophage
combinations. However, the evolution of bacteriophage
resistance in vitro does not seem relevant to in vivo
scenarios, in which bacteria replicate more slowly and are
challenged by more difficult environmental conditions. A
previous study (Capparelli et al., 2007) found a mean
resistance frequency of 1.261028 for S. aureus treated with
bacteriophages in vitro. However, the researchers were
unable to isolate any bacteriophage-resistant S. aureus
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strains in vivo. Indeed, even though the resistance of
bacteria to the bacteriophage cocktails used here was not
specifically studied, we previously found that the presence
of residual bacteria did not globally hinder planimetric or
histological improvement (Mendes et al., 2013). In the
current study, the greatest reduction in bacterial counts
occurred at 3 h, and regrowth was observed at 5 h, which
enabled us to conclude that the best time to give a ‘boost’
application of bacteriophage would be between these two
time points.
In a previous study (unpublished data), we found that the
plaques of the bacteriophages F770/05, F510/08 and F1245/
05 were surrounded by growing opaque halo zones, which
could be related to the presence of a virion-associated
exopolysaccharide depolymerase (Cornelissen et al., 2011).
This and related enzymes have been found to enhance the
biofilm-eradicating activity of bacteriophages compared
with non-depolymerase-producing bacteriophages (Hughes
et al., 1998). Based on genomic analysis, none of our
bacteriophages seemed to produce any obvious extracellular
polysaccharide or exopolysaccharide depolymerase. However,
because bacteriophages that do not produce depolymerases
have also been used in biofilm elimination (Chibeu et al.,
2012), we sought to investigate the effect of bacteriophage
combinations on the viability of target bacterial cells in pre-
formed biofilms at 4 and 24 h. Here, assays using an IM of
10 produced nearly identical results as assays using an IM of
100, with two exceptions. First, we observed different results
between an IM of 10 and an IM of 100 after 4 h for A.
baumannii; however, this discrepancy may have arisen
because only one bacteriophage was used. When previous
experiments used a combination of two bacteriophages, the
IM doubled, producing synergistic results (Abedon &
Thomas-Abedon, 2010). Secondly, differences between
IMs were observed after 24 h for S. aureus. This result
may have occurred because the receptor for the bacterio-
phage F44/10, which we speculate to be N-acetylglucosa-
mine in the cell-wall teichoic acid, is very frequent (relative
to other receptors) in both live cells and bacterial debris.
This property means that active bacteriophages may adsorb
to fragments of lysed cells (debris) instead of live cells, at a
higher rate. This phenomenon may ultimately lead to
injection of the genetic material in a suicidal manner,
eliminating the bacteriophage from the system (Rabinovitch
et al., 2003). Increasing the IM amplifies the probability of
bacteriophage–bacterium interaction, resulting in a true cell
infection. Moreover, in vivo, a bacteriophage dose suffi-
ciently in excess of the target bacterium population (IM
¢100) should be given to account for bacteriophage loss,
dilution (associated with absorption and distribution),
decay and/or inefficiencies of bacteriophage adsorption to
bacteria (e.g. inefficiencies in penetration into biofilms in
vivo).
It is well known that bacterial regrowth occurs after
biofilms have been exposed to antibiotics (Kussell et al.,
2005). One possible way to limit this regrowth is through
multiple dose applications. Our results using multiple dose
applications, as opposed to single-application dosing, are
similar to the results observed in Georgia, where BT is the
current standard of clinical care, and in Poland, where BT
is used as an experimental treatment under a compassion-
ate-use regulatory provision (Abedon et al., 2011; Kutter
et al., 2010; Mie˛dzybrodzki et al., 2012). These results were
also corroborated experimentally in previously published
animal studies (Capparelli et al., 2007). This implies that a
significant proportion of the bacteria in biofilm do not
have genotypic resistance but rather some form of
phenotypic resistance, which is reversible by the modifica-
tion of the causal environmental factors. Various equally
valid and non-mutually excluding theories have been pre-
sented that could explain the possible coexistence dynamics
of bacteriophages and susceptible bacteria: numerical
refuge, physiological refuge and shielding by bacterial
debris. The numerical refuge theory (Chao et al., 1977)
predicts that simple mass-action interactions between
bacteriophages and sensitive and resistant bacteria deter-
mine the stability of the population. Thus, in our study,
when new bacteriophages were added (creating a higher
bacteriophage density), a decline in the number of sensitive
cells resulted. The physiological refuge hypothesis (Lenski
& Levin, 1985) postulates that during certain stages of
bacterial life cycles sensitive bacteria may become trans-
itorily resistant to bacteriophage infection. In the present
study, fresh medium was then added. This altered the life
cycle of the present sensitive bacteria (e.g. from stationary
to logarithmic), thereby potentially converting them from a
temporarily resistant state into a susceptible state. Finally,
the shielding by bacterial debris theory (Rabinovitch et al.,
2003) predicts that active bacteriophages adsorb onto
fragments of lysed cells (debris) and inject their genetic
material in a suicidal manner, thus discounting from the
system as a bacteriophage. In the present study, as new
bacteriophages were added, dead cells were removed, thus
reducing non-productive binding as described. None of
these observations was noted for A. baumannii, perhaps
because this was the only case in which we used a single
bacteriophage, limiting the importance of non-heritable
mechanisms in the reduction in resistance induced by
mutation.
In conclusion, we prepared, purified and characterized
bacteriophage cocktails with a broad spectrum of activity
against S. aureus, P. aeruginosa and A. baumannii strains
that commonly cause DFIs. The complementary studies on
both planktonic cells and established biofilms allowed us to
better evaluate the effects of a high IM (¢10) and a
multiple-dose treatment protocol (every 4 h for 24 h). We
believe that this work takes an important step towards the
future clinical application of BT.
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